A multicenter study to clarify the optimal HCV-RNA negative period during combined therapy with pegylated interferon plus ribavirin in patients with chronic hepatitis caused by HCV genotype 2

Internal Medicine

Volumn 51, Issue 1, 2012, Pages 9-15

  Nagoshi, Sumiko ^a   Koshima, Yohei ^b   Nakamura, Ikuo ^c   Funyu, Junji ^d   Sekine, Chuichi ^e   Harada, Youji ^f   Nishikawa, Ko ^g   Yoshida, Takeshi ^h   Matsui, Atsushi ⁱ   Sotome, Naoki ^j   Toshima, Kenichi ^k   Takegoshi, So ^l   Shiomi, Masao ^m   Tanaka, Masahiko ⁿ   Saito, Akira ^o   Fujiwara, Kenji ^p   Mochida, Satoshi ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b SAITAMA RED CROSS HOSPITAL   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d Chichibu Hospital   (Japan)

^e Saiseikai Kawaguchi General Hospital   (Japan)

^f Toda Chuo General Hospital   (Japan)

^g Ageo Central General Hospital   (Japan)

^h SAITAMA SOCIAL INSURANCE HOSPITAL   (Japan)

ⁱ Shisei Hospital   (Japan)

^j Kumagaya General Hospital   (Japan)

^k Rehabilitation Center   (Japan)

^l Asakadai Central General Hospital   (Japan)

^m Shiomi Hospital   (Japan)

ⁿ Kan etsu Hospital   (Japan)

^o National Hospital Organization Nishisaitama Chuo National Hospital   (Japan)

^p YOKOHAMA ROSAI HOSPITAL   (Japan)

more..

Author keywords

Chronic hepatitis; Genotype 2; HCV; Pegylated interferon; Rapid virological response; Ribavirin; Sustained virological response

Indexed keywords

PEGINTERFERON ALPHA2B; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CLINICAL FEATURE; CLINICAL TRIAL; DEPRESSION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEMOLYTIC ANEMIA; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; RETINOPATHY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 84855219532     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.6237     Document Type: Article

References (19)

1. Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 55: 69-75, 2011.
2. Sakamoto N, Nakagawa M, Tanaka Y, et al. Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b. J Med Virol 83: 871-878, 2011.
3. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 352: 2609-2617, 2005.
4. Buti M, Lurie Y, Zakharova NG, et al. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology 52: 1201-1207, 2010.
5. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterol 130: 1086-1097, 2006.
6. Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology 47: 43-50, 2008.
7. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 43: 425-433, 2005.
8. Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 56: 553-559, 2007.
9. Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, Zeuzem S. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 28: 397-404, 2008.
10. Slavenburg S, Weggelaar I, van Oijen MG, Drenth JP. Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: a meta-analysis. Antivir Ther 14: 1139-1148, 2009.
11. Inoue Y, Hiramatsu N, Oze T. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin; Reducing drug doses has no impact on rapid and sustained virological responses. J Viral Hepatol 17: 336-344, 2010.
12. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1- infected slow responders. Hepatology 46: 1688-1694, 2007.
13. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965, 2001.
14. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105- 1109, 2009.
15. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401, 2009.
16. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100-1104, 2009.
17. Akuta N, Suzuki F, Kawamura Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and lowdensity lipoprotein cholesterol levels. J Hepatol 46: 403-410, 2007.
18. Akuta N, Suzuki F, Sezaki H, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferonribavirin combination therapy. Intervirology 48: 372-380, 2005.
19. Mangia A, Thompson AJ, Santoro R, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterol 139: 821-827, 2010.